Good News:
The study aims to enroll about 400 participants who test positive for what research indicates is one of the most common genetic drivers of Parkinson’s: mutations in a gene called LRRK2. The drug Biogen and Denali are co-developing, now named BIIB122, is meant to stifle LRRK2, and is being tested against a placebo to see if it can significantly slow the worsening of symptoms in patients with early-stage Parkinson’s.
Bad News:
Results will be available by then end-2031
Do any of you have an ides why is it gonna take so long?
Maybe they anticipate that it will take a long time to recruit (and process) 400 early-stage PwPs with a specific genetic variant in their LRRK2 gene.
Also, they have only listed 2 locations for this multicentre Phase 3 trial, but this could change quite rapidly.
that makes sense.
Sounds like the study that I was going to participate in. (I was ultimately disqualified.) it’s just starting phase 2.
Are they looking for LRRK2 subjects? I have that variant. But I’m also on Sinemet since March.
See also this recent PNT article.
Dosing Begins for Phase 3 LIGHTHOUSE Study of BIIB122:
This recent AlzForum article may also be of interest.
LRRK2 Variants Keep α-Synuclein from Forming Tetramers:
Phase 3 trial of buntanetap for early-stage Parkinson’s nears end
Am I Taking the Wrong Vitamin B12? Adenosylcobalamin (AdoCbl) vs Methylcobalamin (MeCbl)
B12 Adenosylcobalamin form inhibits LRRK2
Colorectal Cancer, Leukemia and Parkinson's Disease and Some Potential Help From None Other Than Melatonin
Positive results for Cerevance’s Parkinson’s drug, phase 2 of CVN424 a GPR6 inverse agonist
